Display options
Cite
Wu J, Chen WK, Zhang W, et al. Network meta-analysis of the efficacy and adverse effects of several treatments for advanced/metastatic prostate cancer. Oncotarget. 2017;8(35):59709-59719doi: 10.18632/oncotarget.19810.
Wu, J., Chen, W. K., Zhang, W., Zhang, J. S., Liu, J. H., Jiang, Y. M., & Fang, K. W. (2017). Network meta-analysis of the efficacy and adverse effects of several treatments for advanced/metastatic prostate cancer. Oncotarget, 8(35), 59709-59719. https://doi.org/10.18632/oncotarget.19810
Wu, Jing, et al. "Network meta-analysis of the efficacy and adverse effects of several treatments for advanced/metastatic prostate cancer." Oncotarget vol. 8,35 (2017): 59709-59719. doi: https://doi.org/10.18632/oncotarget.19810
Wu J, Chen WK, Zhang W, Zhang JS, Liu JH, Jiang YM, Fang KW. Network meta-analysis of the efficacy and adverse effects of several treatments for advanced/metastatic prostate cancer. Oncotarget. 2017 Aug 02;8(35):59709-59719. doi: 10.18632/oncotarget.19810. eCollection 2017 Aug 29. PMID: 28938674; PMCID: PMC5601770.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Aug 02;8(35):59709-59719. doi: 10.18632/oncotarget.19810. eCollection 2017 Aug 29.

Network meta-analysis of the efficacy and adverse effects of several treatments for advanced/metastatic prostate cancer.

Oncotarget

Jing Wu, Wei-Kang Chen, Wei Zhang, Jin-Song Zhang, Jian-He Liu, Yong-Ming Jiang, Ke-Wei Fang

Affiliations

  1. Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Kunming Medical University, Kunming 650500, P.R. China.
  2. Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming 650101, P.R. China.

PMID: 28938674 PMCID: PMC5601770 DOI: 10.18632/oncotarget.19810

Abstract

This network meta-analysis was conducted to compare the efficacy and adverse effects of several treatments for advanced/metastatic prostate cancer (PC). The PubMed and Cochrane Library databases were searched for randomized controlled trials of treatments for advanced/metastatic PC. Eighteen studies covering 6,340 patients were included in this analysis. The calculated were odds ratios, 95% confidence intervals, and the surface under the cumulative ranking (SUCRA) curve. Pairwise meta-analysis showed that overall survival rates achieved with radiotherapy or endocrine therapy were lower than obtained with radiotherapy + endocrine therapy. The endocrine therapy includes estrogen therapy, luteinizing hormone-releasing hormone agonist (LHRH-A), anti-androgen therapy (ADT), ADT + LHRH-A and estrogen therapy + LHRH-A, and its SUCRA values indicated that for overall response rate, estrogen therapy + LHRH-A ranked the highest (92.6%); for overall survival rate, ADT ranked the highest (75.2%); for anemia, estrogen therapy ranked the highest (88.2%); and for diarrhea and hot flushes, ADT ranked the highest (diarrhea, 87.4%; hot flushes, 89.3%). Cluster analysis on the endocrine therapy showed that ADT + LHRH-A achieved the highest overall survival and overall response rates in the treatment of advanced/metastatic PC. Estrogen therapy and ADT had the lowest incidences of diarrhea and anemia. Thus, combined radiotherapy + endocrine therapy had higher overall survival rate, and among the endocrine therapy, in terms of overall response rate and overall survival rate, ADT + LHRH-A may be a better regimen in the treatment of advanced or metastatic PC.

Keywords: adverse effects; efficacy; endocrine therapy; prostate cancer; randomized controlled trials

Conflict of interest statement

CONFLICTS OF INTEREST None.

References

  1. Lancet Oncol. 2011 May;12(5):451-9 - PubMed
  2. Horm Res. 1989;32 Suppl 1:69-76 - PubMed
  3. JAMA. 2008 Jun 18;299(23):2760-9 - PubMed
  4. J Urol. 1995 Aug;154(2 Pt 1):424-8 - PubMed
  5. Lancet. 1999 May 15;353(9165):1641-8 - PubMed
  6. J Bone Miner Res. 2002 Jun;17(6):1051-6 - PubMed
  7. Urol Int. 1996;56 Suppl 1:13-7 - PubMed
  8. Lancet. 2002 Jul 13;360(9327):103-6 - PubMed
  9. Trials. 2017 Mar 7;18(1):106 - PubMed
  10. J Clin Oncol. 2015 Jul 1;33(19):2143-50 - PubMed
  11. J Clin Epidemiol. 2011 Feb;64(2):163-71 - PubMed
  12. Lancet. 2009 Jan 24;373(9660):301-8 - PubMed
  13. Oncologist. 1997;2(1):18-27 - PubMed
  14. PLoS One. 2015 Apr 13;10(4):e0123153 - PubMed
  15. Bone. 1990;11(4):229-32 - PubMed
  16. PLoS One. 2013 Oct 03;8(10):e76654 - PubMed
  17. Proc Natl Acad Sci U S A. 1989 Feb;86(3):854-7 - PubMed
  18. Int J Urol. 2004 Feb;11(2):103-9 - PubMed
  19. Korean J Urol. 2013 May;54(5):289-96 - PubMed
  20. J Clin Oncol. 1996 Aug;14(8):2250-7 - PubMed
  21. Eur Urol. 2005 Oct;48(4):546-51 - PubMed
  22. N Engl J Med. 2017 Feb 2;376(5):417-428 - PubMed
  23. Prostate Cancer Prostatic Dis. 2007;10(2):194-201 - PubMed
  24. J Clin Oncol. 1999 Jul;17(7):2027-38 - PubMed
  25. Br J Urol. 1992 Jun;69(6):614-20 - PubMed
  26. Gan To Kagaku Ryoho. 2002 Nov;29(11):1951-61 - PubMed
  27. Eur Urol. 2012 Jun;61(6):1079-92 - PubMed
  28. N Engl J Med. 2001 Sep 27;345(13):948-55 - PubMed
  29. J Clin Oncol. 2008 Feb 1;26(4):585-91 - PubMed
  30. Int J Cancer. 2016 Mar 15;138(6):1388-400 - PubMed
  31. Rev Urol. 2004 Winter;6(1):1-4 - PubMed
  32. J Clin Oncol. 2004 Jul 1;22(13):2546-53 - PubMed
  33. Lancet Oncol. 2013 Apr;14(4):306-16 - PubMed
  34. Eur Urol. 2012 Aug;62(2):213-9 - PubMed
  35. Postgrad Med J. 2003 Nov;79(937):643-5 - PubMed
  36. J Clin Periodontol. 2012 Mar;39(3):303-14 - PubMed
  37. J Clin Oncol. 1997 Mar;15(3):1013-21 - PubMed
  38. Urol Clin North Am. 2006 May;33(2):181-90, vi - PubMed
  39. BMC Med. 2013 Jul 04;11:159 - PubMed
  40. Int J Urol. 2005 Jan;12(1):46-61 - PubMed
  41. J Urol. 2006 Aug;176(2):544-7 - PubMed
  42. Int J Cancer. 2010 Dec 15;127(12):2893-917 - PubMed
  43. J Urol. 2011 Jan;185(1):17-23 - PubMed
  44. Expert Opin Pharmacother. 2008 Feb;9(2):211-28 - PubMed
  45. Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1285-90 - PubMed
  46. J Clin Invest. 2000 Dec;106(12):1553-60 - PubMed
  47. Int J Radiat Oncol Biol Phys. 1988 Jun;14(6):1085-91 - PubMed
  48. Cancer. 2001 Sep 15;92(6):1444-50 - PubMed
  49. J Urol. 2000 Mar;163(3):845-50 - PubMed
  50. Prostate. 1991;18(2):139-46 - PubMed
  51. Urology. 1988 Apr;31(4):312-7 - PubMed
  52. J Urol. 1995 Aug;154(2 Pt 1):429-34 - PubMed
  53. Calcif Tissue Int. 1994 Apr;54(4):325-6 - PubMed
  54. BMJ. 2011 Oct 18;343:d5928 - PubMed
  55. Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1243-52 - PubMed
  56. Jpn J Clin Oncol. 2004 Jan;34(1):20-8 - PubMed
  57. N Engl J Med. 1989 Aug 17;321(7):419-24 - PubMed
  58. J Clin Endocrinol Metab. 2003 Jan;88(1):204-10 - PubMed
  59. N Engl J Med. 1997 Jul 31;337(5):295-300 - PubMed
  60. Jpn J Clin Oncol. 2004 Jun;34(6):329-36 - PubMed

Publication Types